Particularly, these authors have classified prostate cancers according to their mRNA microarray signature profiles indicating stem cell expression patterns (stemness), inactivation of the tumor suppressors PTEN and TP53, TMPRSS2-ERG fusion, and activation of some oncogenic pathways [344]. This evidence concerns the gene TMPRSS2 and prostate cancer.